Name: 글로벌 시장 동향
SKU: MD8568
Availability: InStock

보고서 요약(국문)

개요
전 세계 체내 약물 전달 장치 시장은 2023년 379억 달러 규모에 달했으며, 2024년부터 2031년까지 연평균 8.6%의 성장률을 보이며 2031년에는 733억 달러에 이를 것으로 예상됩니다.
체내 약물 전달 장치는 환자에게 직접 약물을 투여하거나 기타 치료 물질을 작용 부위에 전달하기 위해 신체에 착용하도록 설계된 의료 기기입니다. 이러한 장치는 피부, 점막 또는 기타 신체 표면을 통해 약물을 방출하도록 설계되어 약물의 제어되고 표적화된 전달을 제공합니다.
이러한 장치에는 패치, 펌프, 주사기 등 다양한 형태가 있으며, 옷 위 또는 아래에 부착할 수 있습니다. 이러한 장치의 주요 목적은 약물의 지속적이고 제어된 전달을 제공하여 미리 정해진 시간에 정확한 용량을 투여하거나 지속적인 주입을 가능하게 하는 것입니다.
소분자 약물의 피하 투여용 체내 약물 전달 장치는 최대 3ml 용량까지 사용 가능하며, 신체에 부착하는 패치 형태입니다. 일반적인 적용 분야는 수 시간에 걸친 볼루스 투여 및 기저 투여 요법입니다. 이 부착형 장치는 대분자(생물학적 제제)를 피하로 전달하며, 제형화된 약물의 특정 총량을 주기적으로 투여해야 하는 치료법에 적합하도록 설계되었습니다. 일반적인 적용 분야에는 단클론 항체(mAb)와 같은 단백질이 포함됩니다.
시장 동향: 주요 동인
만성 질환 발병률 증가 및 환자들의 첨단 약물 전달 시스템 선호
전 세계 온바디 약물 전달 장치 시장의 수요는 여러 요인에 의해 주도되고 있습니다. 주요 요인 중 하나는 만성 질환 발병률 증가와 환자들의 첨단 약물 전달 시스템 선호입니다.
당뇨병, 관절염, 고혈압, 암과 같은 만성 질환의 유병률 증가는 온바디 약물 전달 장치에 대한 수요를 촉진하는 주요 요인입니다. 이러한 장치는 정확한 투약, 복약 순응도 향상, 치료 반응 변동성 감소를 통해 만성 질환을 보다 효과적으로 관리할 수 있도록 합니다.
환자들은 기존 약물 전달 방식보다 온바디 약물 전달 장치가 갖는 장점 때문에 점점 더 선호하고 있습니다. 이러한 장점에는 높은 정밀도, 더 적은 투여량 증가, 가정용 사용 가능성, 자동 바늘 삽입 및 회수, 폐색 감지, 표준 유리 카트리지 사용 등이 포함됩니다. 부작용을 최소화하고 치료 효과를 높이면서 특정 세포 또는 조직을 정확하게 표적화할 수 있는 능력은 이러한 첨단 약물 전달 시스템의 도입을 촉진하고 있습니다.
또한, 업계 주요 기업들의 파트너십 및 협력, 제품 출시 및 승인과 같은 전략은 이러한 시장 성장을 견인할 것입니다. 예를 들어, 2023년 3월 Stevanato Group S.p.A.는 Thermo Fisher Scientific과 협력하여 피하 투여를 위한 완전 통합형 체내 약물 전달 시스템 플랫폼을 시장에 출시한다고 발표했습니다.
또한, 2023년 4월 Medtronic은 Smart Guard 기술을 통해 손가락 채혈이 필요 없는 Guardian 4 센서가 탑재된 MiniMed 780G 시스템이 미국 식품의약국(FDA)의 승인을 받았다고 발표했습니다. 이 중요한 성과는 기저(배경) 및 볼루스(식사 시) 인슐린 필요량 모두에 대해 5분마다 혈당 수치를 자동으로 조정 및 보정하는(†) 유일한 식사 감지 기술 시스템의 승인을 의미합니다. 이 시스템은 사용자가 볼루스 투여를 잊거나 식사의 탄수화물 양을 과소평가하는 경우를 대비하여 인슐린을 공급합니다.
제한 요인
기기 및 치료 비용의 높은 부담, 주사침 자상 및 환자 불편함의 위험, 규제 문제, 그리고 사람들의 인식 부족과 같은 요인들이 시장 성장을 저해할 것으로 예상됩니다.
이 보고서에 대한 자세한 내용은 샘플을 요청하십시오.
세그먼트 분석
전 세계 온바디 약물 전달 장치 시장은 기기 유형, 분자 유형, 적용 분야, 유통 채널 및 지역별로 세분화됩니다.
웨어러블 주사기 부문은 전 세계 온바디 약물 전달 장치 시장 점유율의 약 62.8%를 차지했습니다.
웨어러블 주사기 부문은 예측 기간 동안 가장 큰 시장 점유율을 유지할 것으로 예상됩니다. 웨어러블 주사 시스템은 신체에 부착되어 최적의 시간에 환자에게 설정된 용량을 자동으로 투여하는 약물 전달 장치입니다. 웨어러블 주사 시스템은 만성 질환 관리의 자연스러운 진화를 나타냅니다. 이러한 질환에 대한 대응으로 웨어러블 주사 시스템이 등장함에 따라 장치 설계 및 테스트와 관련된 완전히 새로운 과제들도 생겨났습니다.
또한, 업계 주요 업체들의 제품 출시 및 승인은 시장 성장을 견인하는 데 도움이 됩니다. 예를 들어, 2024년 2월 LTS LOHMANN Therapie-Systeme AG는 LTS Sorrel 웨어러블 약물 전달 플랫폼을 활용한 UDENYCA 온바디 인젝터(OBI)를 출시했습니다. UDENYCA(pegfilgrastim-cbqv)는 항암화학요법 다음 날 투여하여 발열성 호중구 감소증으로 나타나는 감염 발생률을 감소시키는 바이오시밀러 페그필그라스팀입니다.

또한, 2023년 9월 Enable Injections, Inc.는 미국 식품의약국(FDA)이 Apellis Pharmaceuticals, Inc.에서 발작성 야간 혈색소뇨증(PNH) 성인 환자를 대상으로 시판 중인 EMPAVELI(pegcetacoplan)의 피하 투여용 EMPAVELI Injector(enFuse)를 승인했다고 발표했습니다. EMPAVELI Injector는 환자의 일상생활에 최소한의 지장을 주면서 자가 투여 경험을 간소화하도록 설계된 소형 웨어러블 주사기입니다.
이 외에도 주요 기업들의 혁신적인 개발, 투자 및 인수 합병이 이 시장 부문의 성장을 견인하고 있습니다. 예를 들어, 2023년 1월 Eitan Medical은 웨어러블 약물 전달 플랫폼을 위한 새로운 제조 시설을 본사에 개설했습니다. 이 새로운 제조 시설은 약물 전달 장치 생산을 지원합니다.

마찬가지로, 2023년 4월 LTS Lohmann은 이스라엘 네타냐에 본사를 둔 Eitan Medical Ltd.의 자회사인 Sorrel 웨어러블 주사 장치 사업부를 인수했습니다.
지역 분석
북미는 전 세계 웨어러블 약물 전달 장치 시장 점유율의 약 42.1%를 차지했습니다.
북미 지역은 만성 질환 발생률 증가, 자가 투여 약물 수요 증가, 그리고 잘 발달된 의료 인프라로 인해 예측 기간 동안 가장 큰 시장 점유율을 유지할 것으로 예상되며, 이러한 요인들이 해당 지역 시장 성장을 견인할 것입니다.
또한, 다수의 주요 업체들의 존재, 기술 발전, 신제품 출시 및 승인이 시장 성장을 촉진하고 있습니다. 예를 들어, 2024년 2월 Tandem Diabetes Care, Inc.는 당뇨병 환자를 위한 세계에서 가장 작고 내구성이 뛰어난 자동 인슐린 전달 시스템인 Tandem Mobi의 미국 시장 출시를 발표했습니다. 이 회사는 이미 미국 내 고객들에게 주문 접수 및 배송을 시작했습니다.

또한, scPharmaceuticals는 5년간의 노력과 두 번의 실패 끝에 2022년 10월, 울혈성 심부전 환자를 위한 체내 주입기인 푸로식스(Furoscix)의 FDA 승인을 마침내 획득했습니다. 이번 승인으로 푸로식스는 악화되는 심부전 환자를 위한 최초의 자가 투여형 피하 루프 이뇨제가 되었습니다.
미국 식품의약국(FDA)은 뉴욕 심장 협회(NYHA) 2급 및 3급 만성 심부전 성인 환자의 체액 과다로 인한 울혈 치료를 위해 푸로식스(푸로세미드 주사)를 승인했습니다.

시장 세분화
기기 유형별
• 웨어러블 주사기
• 주입 펌프
• 기타
분자 유형별
• 소분자
• 대분자
적용 분야별
• 심혈관 질환
• 암
• 당뇨병
• 자가면역 질환
• 기타
유통 채널별
• 병원 약국
• 온라인 약국
• 소매 약국
지역별
• 북미
o 미국
o 캐나다
o 멕시코
• 유럽
o 독일
o 영국
o 프랑스
o 스페인
o 이탈리아
o 기타 유럽
• 남미
o 브라질
o 아르헨티나
o 기타 남미
• 아시아 태평양
o 중국
o 인도
o 일본
o 한국
o 기타 아시아 태평양
• 중동 및 아프리카
경쟁 환경
웨어러블 약물 전달 기기 시장의 주요 글로벌 업체로는 Gerresheimer AG, NOVO Engineering, West Pharmaceutical Services, Inc., Enable Injections, Stevanato Group 등이 있습니다. LTS Lohmann Therapie-Systeme AG, BD, Coherus BioSciences, Inc., Tandem Diabetes Care, Inc., Battelle 등이 있습니다.
주요 개발 사항
 2024년 1월, Aptar Digital Health와 Gerresheimer는 통합 암 치료 솔루션을 개발했습니다. Aptar Digital Health의 독자적인 SaMD 플랫폼과 Gerresheimer의 대형 생물학적 제제 피하 투여 장치인 Gx SensAir를 결합한 이 통합 솔루션은 전반적인 치료 순응도와 임상 결과를 개선하는 것을 목표로 합니다.

 2023년 12월, Stevanato Group은 여러 피하 치료제에 적용 가능한 새로운 특허받은 체내 투여 시스템 Vertiva를 출시했습니다. 다양한 투여 방식에 맞춰 설계된 이 장치는 생물학적 제제와 소분자 약물의 투여를 용이하게 합니다.

보고서 구매 이유

• 기기 유형, 분자 유형, 적용 분야, 유통 채널 및 지역별 글로벌 온바디 약물 전달 장치 시장 세분화를 시각화하고 주요 상업적 자산과 주요 업체를 파악합니다.

• 트렌드 분석 및 공동 개발을 통해 사업 기회를 발굴합니다.

• 모든 세그먼트를 포함한 온바디 약물 전달 장치 시장의 다양한 데이터가 담긴 엑셀 자료를 제공합니다.

• 심층적인 질적 인터뷰와 연구를 바탕으로 종합적인 분석 결과를 담은 PDF 보고서를 제공합니다.

• 주요 업체들의 핵심 제품을 모두 포함한 제품 맵핑 자료를 엑셀 파일로 제공합니다.

글로벌 온바디 약물 전달 장치 시장 보고서는 약 70개의 표, 63개의 그림, 184페이지 분량입니다.
대상 고객 (2023년 기준)
• 제조업체/구매자
• 산업 투자자/투자 은행가
• 연구 전문가
• 신흥 기업

보고서 요약(영어 원문)

Overview
The global on-body drug delivery devices market reached US$ 37.9 billion in 2023 and is expected to reach US$ 73.3 billion by 2031 growing with a CAGR of 8.6% during the forecast period 2024-2031.
On-body drug delivery devices are medical devices that are designed to be worn on the body to deliver medications directly to patients or other therapeutic substances to the site of action. These devices are designed to release drugs through the skin, mucous membranes, or other body surfaces, providing a controlled and targeted delivery of medication.
These devices include various forms such as patches, pumps, and injectors, which can be attached to the body either under or over clothing. The primary purpose of these devices is to provide sustained and controlled delivery of medications, allowing for precise dosing at predetermined times or continuous infusion.
The on-body drug delivery device for the subcutaneous administration of small-molecule drugs is available for volumes up to 3 ml. It is patched onto the body. Typical applications are bolus and basal regimens over several hours. This patched-on device delivers large molecules (biologics) subcutaneously and is designed for therapies that periodically require a certain total quantity of a formulated drug. Typical applications include proteins such as monoclonal antibodies (mAbs).
Market Dynamics: Drivers
Rise in incidences of chronic diseases & patients' shift toward advanced drug delivery systems
The demand for the global on-body drug delivery devices market is driven by multiple factors. One of the key factors is the rise in incidences of chronic diseases & patients' shift toward advanced drug delivery systems.
The increasing prevalence of chronic conditions such as diabetes, arthritis, hypertension, and cancer is a major factor driving the demand for on-body drug delivery devices. These devices enable more effective management of chronic diseases by allowing for precise dosing, improved adherence, and reduced variability in treatment response.
Patients are increasingly preferring on-body drug delivery devices due to their advantages over traditional drug delivery methods. These advantages include higher precision, lower dosing increments, home-use capabilities, automatic needle insertion and retraction, occlusion detection, and the use of standard glass cartridges. The ability to accurately target specific cells or tissues while minimizing side effects and increasing therapeutic efficacy is driving the adoption of these advanced drug delivery systems.
Moreover, key players in the industry strategies such as partnerships & collaborations, and product launches & approvals would propel this market growth. For instance, in March 2023, Stevanato Group S.p.A. announced its collaboration with Thermo Fisher Scientific to bring a fully integrated on-body delivery system platform for subcutaneous administration to the market.
Also, in April 2023, Medtronic announced the U.S. Food and Drug Administration (FDA) approval of its MiniMed 780G system with the Guardian 4 sensor requiring no finger sticks while in Smart Guard technology. This milestone marks the approval of the only system with meal detection technology that provides automatic adjustments and corrections† to sugar levels every 5 minutes§ for both basal (background) and bolus (mealtime) insulin needs. The system provides insulin to help account for when users occasionally forget to bolus or underestimate the number of carbs in their meals.
Restraints
Factors such as the high costs of devices & treatment, the risk of needlestick injuries & patient discomfort, regulatory challenges, and lack of awareness among people, are expected to hamper the market.
For more details on this report - Request for Sample
Segment Analysis
The global on-body drug delivery devices market is segmented based on device type, molecule type, application, distribution channels, and region.
The wearable injectors segment accounted for approximately 62.8% of the global on-body drug delivery devices market share
The wearable injectors segment is expected to hold the largest market share over the forecast period. Wearable injection systems are drug-delivery devices that adhere to the body, automatically delivering set doses to the patient at optimal times. Wearable injection systems represent the natural evolution of chronic disease management. As wearable injection systems have emerged in response to these conditions, so has a completely new set of challenges regarding device design and testing.
Moreover, key players in the industry product launches and approvals help to drive this segment growth in the market. For instance, in February 2024, LTS LOHMANN Therapie-Systeme AG launched its UDENYCA on-body injector (OBI) utilizing the LTS Sorrel wearable drug delivery platform. UDENYCA (pegfilgrastim-cbqv) is a biosimilar pegfilgrastim administered the day after chemotherapy to decrease the incidence of infection as manifested by febrile neutropenia.
Also, in September 2023, Enable Injections, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved the EMPAVELI Injector (enFuse) for the subcutaneous delivery of EMPAVELI (pegcetacoplan), which is commercialized in the United States by Apellis Pharmaceuticals, Inc. for adults with paroxysmal nocturnal hemoglobinuria (PNH). The EMPAVELI Injector is a compact, wearable injector designed to streamline the self-administration experience with minimal disruption to patients’ daily lives.
In addition, major players' innovative developments, investments, and mergers & acquisitions drive this segment's growth in the market. For instance, in January 2023, Eitan Medical opened a new manufacturing facility for a wearable drug delivery platform. The new manufacturing facility at its headquarters to support drug-delivery device production.
Similarly, in April 2023, LTS Lohmann acquired the Sorrel wearable injection device business headquartered in Netanya, Israel, a part of Eitan Medical Ltd.
Geographical Analysis
North America accounted for approximately 42.1% of the global on-body drug delivery devices market share
North America region is expected to hold the largest market share over the forecast period owing to the rising incidence of chronic diseases, demand for self-administration medications, and well-advanced healthcare infrastructure propelling the market growth in this region.
Moreover, a major number of key players' presence, technological advancements, and product launches & approvals drive the market growth. For instance, in February 2024, Tandem Diabetes Care, Inc. announced the United States commercial launch of its new Tandem Mobi, the world’s smallest, durable automated insulin delivery system for people living with diabetes. The company has begun taking orders and shipping to eligible customers in the United States.
Also, in October 2022, after five years and two unsuccessful attempts, scPharmaceuticals finally pushed its on-body infusor for congestive heart failure across the FDA finish line. With the approval, Furoscix becomes the first self-administered, subcutaneous loop diuretic for those with worsening HF.
The Food and Drug Administration (FDA) approved Furoscix (furosemide injection) for the treatment of congestion due to fluid overload in adult patients with New York Heart Association (NYHA) Class II and Class III chronic heart failure.
Market Segmentation
By Devices Type
• Wearable Injectors
• Infusion Pumps
• Others
By Molecules Type
• Small Molecule
• Large Molecule
By Application
• Cardiovascular Diseases
• Cancer
• Diabetes
• Auto-immune Disease
• Others
By Distribution Channel
• Hospital Pharmacies
• Online Pharmacies
• Retail Pharmacies
By Region
• North America
o U.S.
o Canada
o Mexico
• Europe
o Germany
o U.K.
o France
o Spain
o Italy
o Rest of Europe
• South America
o Brazil
o Argentina
o The rest of South America
• Asia-Pacific
o China
o India
o Japan
o South Korea
o Rest of Asia-Pacific
• Middle East and Africa
Competitive Landscape
The major global players in the on-body drug delivery devices market include Gerresheimer AG, NOVO Engineering, West Pharmaceutical Services, Inc., Enable Injections, Stevanato Group, LTS Lohmann Therapie-Systeme AG, BD, Coherus BioSciences, Inc., Tandem Diabetes Care, Inc, and Battelle among others.
Key Developments
 In January 2024, Aptar Digital Health and Gerresheimer developed an integrated cancer therapy solution. By connecting Aptar Digital Health’s proprietary SaMD platform with Gx SensAir, Gerresheimer’s on-body device for the subcutaneous delivery of large biologics molecules, this integrated solution is intended to improve overall treatment adherence and clinical outcomes.
 In December 2023, Stevanato Group introduced the new patented on-body delivery system Vertiva for several subcutaneous therapies. Designed to be adapted to different delivery profiles, the device facilitates the administration of biologics and small-molecule drugs.
Why Purchase the Report?
• To visualize the global on-body drug delivery devices market segmentation based on device type, molecule type, application, distribution channels, and region and understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of the on-body drug delivery devices market with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping is available in Excel consisting of key products of all the major players.
The global on-body drug delivery devices market report would provide approximately 70 tables, 63 figures, and 184 pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

상세 목차

Table of Contents
1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Devices Type
3.2. Snippet by Molecule Type
3.3. Snippet by Application
3.4. Snippet by Distribution Channels
3.5. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Rise in Incidences of Chronic Diseases & Patients' Shift Toward Advanced Drug Delivery Systems
4.1.1.2. Increasing Demand for Biologics and Large-Volume Injections
4.1.2. Restraints
4.1.2.1. High Cost for Devices & Treatment
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter’s Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
6. By Devices Type
6.1. Introduction
6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Devices Type
6.1.2. Market Attractiveness Index, By Devices Type
6.2. Wearable Injectors *
6.2.1. Introduction
6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. Infusion Pumps
6.4. Others
7. By Molecule Type
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Molecule Type
7.1.2. Market Attractiveness Index, By Molecule Type
7.2. Small Molecule *
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Large Molecule
8. By Application
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application Market Attractiveness Index, By Application
8.2. Cardiovascular Diseases *
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Cancer
8.4. Diabetes
8.5. Auto-immune Disease
8.6. Others
9. By Distribution Channels
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channels
9.1.2. Market Attractiveness Index, By Distribution Channels
9.2. Hospital Pharmacies *
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Retail Pharmacies
9.4. Online Pharmacies
10. By Region
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
10.1.2. Market Attractiveness Index, By Region
10.2. North America
10.2.1. Introduction
10.2.2. Key Region-Specific Dynamics
10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Devices Type
10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Molecule Type
10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channels
10.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.2.7.1. U.S.
10.2.7.2. Canada
10.2.7.3. Mexico
10.3. Europe
10.3.1. Introduction
10.3.2. Key Region-Specific Dynamics
10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Devices Type
10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Molecule Type
10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channels
10.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.3.7.1. Germany
10.3.7.2. U.K.
10.3.7.3. France
10.3.7.4. Spain
10.3.7.5. Italy
10.3.7.6. Rest of Europe
10.4. South America
10.4.1. Introduction
10.4.2. Key Region-Specific Dynamics
10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Devices Type
10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Molecule Type
10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channels
10.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.4.7.1. Brazil
10.4.7.2. Argentina
10.4.7.3. Rest of South America
10.5. Asia-Pacific
10.5.1. Introduction
10.5.2. Key Region-Specific Dynamics
10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Devices Type
10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Molecule Type
10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channels
10.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.5.7.1. China
10.5.7.2. India
10.5.7.3. Japan
10.5.7.4. South Korea
10.5.7.5. Rest of Asia-Pacific
10.6. Middle East and Africa
10.6.1. Introduction
10.6.2. Key Region-Specific Dynamics
10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Devices Type
10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Molecule Type
10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
10.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channels
11. Competitive Landscape
11.1. Competitive Scenario
11.2. Market Positioning/Share Analysis
11.3. Mergers and Acquisitions Analysis
12. Company Profiles
12.1. Gerresheimer AG *
12.1.1. Company Overview
12.1.2. Product Portfolio and Description
12.1.3. Financial Overview
12.1.4. Key Developments
12.2. NOVO Engineering
12.3. West Pharmaceutical Services, Inc
12.4. Enable Injections
12.5. Stevanato Group
12.6. LTS Lohmann Therapie-Systeme AG
12.7. BD
12.8. Coherus BioSciences, Inc.
12.9. Tandem Diabetes Care, Inc
12.10. Battelle
LIST NOT EXHAUSTIVE
13. Appendix
13.1. About Us and Services
13.2. Contact Us

언급된 주요 기업들

Gerresheimer AG, 4.	Key Developments, NOVO Engineering, West Pharmaceutical Services, Inc, Enable Injections, Stevanato Group, LTS Lohmann Therapie-Systeme AG, BD, Coherus BioSciences, Inc., Tandem Diabetes Care, Inc, Battelle

표 목록 (Tables)

List of Tables

Table 1 Global On-body Drug Delivery Devices Market Value, By Devices Type, 2024, 2029 & 2033 (US$ Million)

Table 2 Global On-body Drug Delivery Devices Market Value, By Molecule Type, 2024, 2029 & 2033 (US$ Million)

Table 3 Global On-body Drug Delivery Devices Market Value, By Application, 2024, 2029 & 2033 (US$ Million)

Table 4 Global On-body Drug Delivery Devices Market Value, By Distribution Channel, 2024, 2029 & 2033 (US$ Million)

Table 5 Global On-body Drug Delivery Devices Market Value, By Region, 2024, 2029 & 2033 (US$ Million)

Table 6 Global On-body Drug Delivery Devices Market Value, By Devices Type, 2024, 2029 & 2033 (US$ Million)

Table 7 Global On-body Drug Delivery Devices Market Value, By Devices Type, 2018-2033 (US$ Million)

Table 8 Global On-body Drug Delivery Devices Market Value, By Molecule Type, 2024, 2029 & 2033 (US$ Million)

Table 9 Global On-body Drug Delivery Devices Market Value, By Molecule Type, 2018-2033 (US$ Million)

Table 10 Global On-body Drug Delivery Devices Market Value, By Application, 2024, 2029 & 2033 (US$ Million)

Table 11 Global On-body Drug Delivery Devices Market Value, By Application, 2018-2033 (US$ Million)

Table 12 Global On-body Drug Delivery Devices Market Value, By Distribution Channel, 2024, 2029 & 2033 (US$ Million)

Table 13 Global On-body Drug Delivery Devices Market Value, By Distribution Channel, 2018-2033 (US$ Million)

Table 14 Global On-body Drug Delivery Devices Market Value, By Region, 2024, 2029 & 2033 (US$ Million)

Table 15 Global On-body Drug Delivery Devices Market Value, By Region, 2018-2033 (US$ Million)

Table 16 North America On-body Drug Delivery Devices Market Value, By Devices Type, 2018-2033 (US$ Million)

Table 17 North America On-body Drug Delivery Devices Market Value, By Molecule Type, 2018-2033 (US$ Million)

Table 18 North America On-body Drug Delivery Devices Market Value, By Application, 2018-2033 (US$ Million)

Table 19 North America On-body Drug Delivery Devices Market Value, By Distribution Channel, 2018-2033 (US$ Million)

Table 20 North America On-body Drug Delivery Devices Market Value, By Country, 2018-2033 (US$ Million)

Table 21 South America On-body Drug Delivery Devices Market Value, By Devices Type, 2018-2033 (US$ Million)

Table 22 South America On-body Drug Delivery Devices Market Value, By Molecule Type, 2018-2033 (US$ Million)

Table 23 South America On-body Drug Delivery Devices Market Value, By Application, 2018-2033 (US$ Million)

Table 24 South America On-body Drug Delivery Devices Market Value, By Distribution Channel, 2018-2033 (US$ Million)

Table 25 South America On-body Drug Delivery Devices Market Value, By Country, 2018-2033 (US$ Million)

Table 26 Europe On-body Drug Delivery Devices Market Value, By Devices Type, 2018-2033 (US$ Million)

Table 27 Europe On-body Drug Delivery Devices Market Value, By Molecule Type, 2018-2033 (US$ Million)

Table 28 Europe On-body Drug Delivery Devices Market Value, By Application, 2018-2033 (US$ Million)

Table 29 Europe On-body Drug Delivery Devices Market Value, By Distribution Channel, 2018-2033 (US$ Million)

Table 30 Europe On-body Drug Delivery Devices Market Value, By Country, 2018-2033 (US$ Million)

Table 31 Asia-Pacific On-body Drug Delivery Devices Market Value, By Devices Type, 2018-2033 (US$ Million)

Table 32 Asia-Pacific On-body Drug Delivery Devices Market Value, By Molecule Type, 2018-2033 (US$ Million)

Table 33 Asia-Pacific On-body Drug Delivery Devices Market Value, By Application, 2018-2033 (US$ Million)

Table 34 Asia-Pacific On-body Drug Delivery Devices Market Value, By Distribution Channel, 2018-2033 (US$ Million)

Table 35 Asia-Pacific On-body Drug Delivery Devices Market Value, By Country, 2018-2033 (US$ Million)

Table 36 Middle East and Africa On-body Drug Delivery Devices Market Value, By Devices Type, 2018-2033 (US$ Million)

Table 37 Middle East and Africa On-body Drug Delivery Devices Market Value, By Molecule Type, 2018-2033 (US$ Million)

Table 38 Middle East and Africa On-body Drug Delivery Devices Market Value, By Application, 2018-2033 (US$ Million)

Table 39 Middle East and Africa On-body Drug Delivery Devices Market Value, By Distribution Channel, 2018-2033 (US$ Million)

Table 40 Middle East and Africa On-body Drug Delivery Devices Market Value, By Country, 2018-2033 (US$ Million)

Table 41 BD: Overview

Table 42 BD: Product Portfolio

Table 43 BD: Key Developments

Table 44 Gerresheimer AG: Overview

Table 45 Gerresheimer AG: Product Portfolio

Table 46 Gerresheimer AG: Key Developments

Table 47 NOVO Engineering: Overview

Table 48 NOVO Engineering: Product Portfolio

Table 49 NOVO Engineering: Key Developments

Table 50 West Pharmaceutical Services, Inc.: Overview

Table 51 West Pharmaceutical Services, Inc.: Product Portfolio

Table 52 West Pharmaceutical Services, Inc.: Key Developments

Table 53 Enable Injections: Overview

Table 54 Enable Injections: Product Portfolio

Table 55 Enable Injections: Key Developments

Table 56 Stevanato Group: Overview

Table 57 Stevanato Group: Product Portfolio

Table 58 Stevanato Group: Key Developments

Table 59 LTS Lohmann Therapie-Systeme AG: Overview

Table 60 LTS Lohmann Therapie-Systeme AG: Product Portfolio

Table 61 LTS Lohmann Therapie-Systeme AG: Key Developments

Table 62 Coherus BioSciences, Inc.: Overview

Table 63 Coherus BioSciences, Inc.: Product Portfolio

Table 64 Coherus BioSciences, Inc.: Key Developments

Table 65 Tandem Diabetes Care, Inc: Overview

Table 66 Tandem Diabetes Care, Inc: Product Portfolio

Table 67 Tandem Diabetes Care, Inc: Key Developments

Table 68 Battelle: Overview

Table 69 Battelle: Product Portfolio

Table 70 Battelle: Key Developments

그림 목록 (Figures)

List of Figures

Figure 1 Global On-body Drug Delivery Devices Market Value, 2018-2033 (US$ Million)

Figure 2 Global On-body Drug Delivery Devices Market Share, By Devices Type, 2024 & 2033 (%)

Figure 3 Global On-body Drug Delivery Devices Market Share, By Molecule Type, 2024 & 2033 (%)

Figure 4 Global On-body Drug Delivery Devices Market Share, By Application, 2024 & 2033 (%)

Figure 5 Global On-body Drug Delivery Devices Market Share, By Distribution Channel, 2024 & 2033 (%)

Figure 6 Global On-body Drug Delivery Devices Market Share, By Region, 2024 & 2033 (%)

Figure 7 Global On-body Drug Delivery Devices Market Y-o-Y Growth, By Devices Type, 2024-2033 (%)

Figure 8 Wearable Injectors On-body Drug Delivery Devices Market Value, 2018-2033 (US$ Million)

Figure 9 Infusion Pumps On-body Drug Delivery Devices Market Value, 2018-2033 (US$ Million)

Figure 10 Others On-body Drug Delivery Devices Market Value, 2018-2033 (US$ Million)

Figure 11 Global On-body Drug Delivery Devices Market Y-o-Y Growth, By Molecule Type, 2024-2033 (%)

Figure 12 Small Molecule Molecule Type in Global On-body Drug Delivery Devices Market Value, 2018-2033 (US$ Million)

Figure 13 Large Molecule Molecule Type in Global On-body Drug Delivery Devices Market Value, 2018-2033 (US$ Million)

Figure 14 Global On-body Drug Delivery Devices Market Y-o-Y Growth, By Application, 2024-2033 (%)

Figure 15 Cardiovascular Diseases Application in Global On-body Drug Delivery Devices Market Value, 2018-2033 (US$ Million)

Figure 16 Cancer Application in Global On-body Drug Delivery Devices Market Value, 2018-2033 (US$ Million)

Figure 17 Diabetes Application in Global On-body Drug Delivery Devices Market Value, 2018-2033 (US$ Million)

Figure 18 Auto-immune Disease Application in Global On-body Drug Delivery Devices Market Value, 2018-2033 (US$ Million)

Figure 19 Others Application in Global On-body Drug Delivery Devices Market Value, 2018-2033 (US$ Million)

Figure 20 Global On-body Drug Delivery Devices Market Y-o-Y Growth, By Distribution Channel, 2024-2033 (%)

Figure 21 Hospital Pharmacies Distribution Channel in Global On-body Drug Delivery Devices Market Value, 2018-2033 (US$ Million)

Figure 22 Retail Pharmacies Distribution Channel in Global On-body Drug Delivery Devices Market Value, 2018-2033 (US$ Million)

Figure 23 Online Pharmacies Distribution Channel in Global On-body Drug Delivery Devices Market Value, 2018-2033 (US$ Million)

Figure 24 Global On-body Drug Delivery Devices Market Y-o-Y Growth, By Region, 2024-2033 (%)

Figure 25 North America On-body Drug Delivery Devices Market Value, 2018-2033 (US$ Million)

Figure 26 North America On-body Drug Delivery Devices Market Share, By Devices Type, 2024 & 2033 (%)

Figure 27 North America On-body Drug Delivery Devices Market Share, By Molecule Type, 2024 & 2033 (%)

Figure 28 North America On-body Drug Delivery Devices Market Share, By Application, 2024 & 2033 (%)

Figure 29 North America On-body Drug Delivery Devices Market Share, By Distribution Channel, 2024 & 2033 (%)

Figure 30 North America On-body Drug Delivery Devices Market Share, By Country, 2024 & 2033 (%)

Figure 31 South America On-body Drug Delivery Devices Market Value, 2018-2033 (US$ Million)

Figure 32 South America On-body Drug Delivery Devices Market Share, By Devices Type, 2024 & 2033 (%)

Figure 33 South America On-body Drug Delivery Devices Market Share, By Molecule Type, 2024 & 2033 (%)

Figure 34 South America On-body Drug Delivery Devices Market Share, By Application, 2024 & 2033 (%)

Figure 35 South America On-body Drug Delivery Devices Market Share, By Distribution Channel, 2024 & 2033 (%)

Figure 36 South America On-body Drug Delivery Devices Market Share, By Country, 2024 & 2033 (%)

Figure 37 Europe On-body Drug Delivery Devices Market Value, 2018-2033 (US$ Million)

Figure 38 Europe On-body Drug Delivery Devices Market Share, By Devices Type, 2024 & 2033 (%)

Figure 39 Europe On-body Drug Delivery Devices Market Share, By Molecule Type, 2024 & 2033 (%)

Figure 40 Europe On-body Drug Delivery Devices Market Share, By Application, 2024 & 2033 (%)

Figure 41 Europe On-body Drug Delivery Devices Market Share, By Distribution Channel, 2024 & 2033 (%)

Figure 42 Europe On-body Drug Delivery Devices Market Share, By Country, 2024 & 2033 (%)

Figure 43 Asia-Pacific On-body Drug Delivery Devices Market Value, 2018-2033 (US$ Million)

Figure 44 Asia-Pacific On-body Drug Delivery Devices Market Share, By Devices Type, 2024 & 2033 (%)

Figure 45 Asia-Pacific On-body Drug Delivery Devices Market Share, By Molecule Type, 2024 & 2033 (%)

Figure 46 Asia-Pacific On-body Drug Delivery Devices Market Share, By Application, 2024 & 2033 (%)

Figure 47 Asia-Pacific On-body Drug Delivery Devices Market Share, By Distribution Channel, 2024 & 2033 (%)

Figure 48 Asia-Pacific On-body Drug Delivery Devices Market Share, By Country, 2024 & 2033 (%)

Figure 49 Middle East and Africa On-body Drug Delivery Devices Market Value, 2018-2033 (US$ Million)

Figure 50 Middle East and Africa On-body Drug Delivery Devices Market Share, By Devices Type, 2024 & 2033 (%)

Figure 51 Middle East and Africa On-body Drug Delivery Devices Market Share, By Molecule Type, 2024 & 2033 (%)

Figure 52 Middle East and Africa On-body Drug Delivery Devices Market Share, By Application, 2024 & 2033 (%)

Figure 53 Middle East and Africa On-body Drug Delivery Devices Market Share, By Distribution Channel, 2024 & 2033 (%)

Figure 54 BD: Financials

Figure 55 Gerresheimer AG: Financials

Figure 56 NOVO Engineering: Financials

Figure 57 West Pharmaceutical Services, Inc.: Financials

Figure 58 Enable Injections: Financials

Figure 59 Stevanato Group: Financials

Figure 60 LTS Lohmann Therapie-Systeme AG: Financials

Figure 61 Coherus BioSciences, Inc.: Financials

Figure 62 Tandem Diabetes Care, Inc: Financials

Figure 63 Battelle: Financials

글로벌 체내 약물 전달 장치 시장 – 2024-2031

Global On-body Drug Delivery Devices Market - 2024-2031